CClinicalTrials.gg
Status unknownNCT02583347Updated Aug 28, 2017

Sleep Disturbance in Patients With End-Stage Renal Disease

An observational study in Renal Failure Chronic Requiring Hemodialysis and Sleep Disorders, sponsored by Beaumont Hospital. Status unknown at 1 site in Ireland. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2017-08-28.

Sponsored by Beaumont Hospital · Observational

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
16 Years and older
Sex
All
01

Study summary

Sleep disorders are common in patients who have chronic kidney disease (CKD). Insomnia is reported in up to 50% of patients treated with hemodialysis compared to 12% of a control population. Restless leg syndrome (RLS) and periodic limb movement disorder (PLM) have been described in 30 to 70% of patients with end stage kidney disease (ESKD). Patients with CKD have also been reported to have a very high prevalence of sleep apnoea disorder. Conventional hemodialysis and peritoneal dialysis do not appear to improve sleep disorders in patients with CKD. There is emerging evidence that nocturnal HD can lead to improvements in sleep quality. Transplantation is thought to improve sleep-related disorders in some but not all patients.

Project Aims

The aims of this project were three-fold:

  1. To perform detailed assessment of sleep quality in a cohort of Irish patients with ESRD
  2. To assess the feasability and tolerability of unattended home PSG and wrist actigraphy as diagnostic tools in this cohort
  3. To assess the impact of a change in RRT modality on sleep quality in Irish patients with ESRD
Read the detailed description

Patients will not selected based on presence/absence of sleep disturbance. Patients will be prioritized for recruitment if they were active on the transplant waitlist or a change in RRT modality is planned.

Patients will be selected for inclusion if they were >16 years old, competent to independently undertake the informed consent process and are currently on RRT or planned to start RRT in the next three months. The following exclusion criteria will be applied: dementia, active malignancy, major psychiatric disorder, home oxygen therapy, CPAP therapy, and regular benzodiazepine use.

Baseline Evaluation

Baseline evaluation includes the following:

  • Demographics and clinical parameters including medications and caffeine intake
  • Dialysis prescription and adequacy (weekly standardised Kt/V)
  • Laboratory data (haemoglobin, iron, phosphate, PTH)
  • Subjective sleep quality as measured by Berlin Questionnaire, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index and International Restless Leg Syndrome Questionnaire
  • Quality of Life as assessed by the 36 Item Short Form Survey (SF-36), Beck Depression Index and Centre for Epidemiologic Studies-Depression Scale
  • Cognitive assessment as measured by Trail Making Tests 1 \& 2, Category Fluency, Controlled Oral Word Association Test and Hopkins Verbal Learning Test
  • Unattended home polysomnography set-up up by investigator who was blinded to the results of the above assessments
  • Wrist actigraphy for 3-5 continuous days (Philips Respironics Actiwatch 2 System)

Follow-up Evaluation following RRT Modality Change Follow-up evaluation will be performed in the same way as baseline evaluation at three - six months post switch of RRT modality. As the impact of NHHD is of particular interest, follow-up evaluation will be performed at one and six months post switch to NHHD in those patients who switched to NHHD. The follow-up home PSG was performed on an 'on-dialysis' night and an 'off-dialysis' night to evaluate the impact of the nocturnal procedure itself on sleep.

Data Analysis A sleep technician, blinded to the questionnaire results, compiles the PSG analysis and reports in accordance with the American Academy of Sleep Medicine (AASM) manual for the Scoring of Sleep and Associated Events (40). Actigraphy analysis is reported using Philips Respironics Actiwatch Software.

Statistical methods Statistical analysis will be performed using Stata V14 and Prism V6. All p values \<0.05 will be considered statistically significant. Mean data and standard deviation data will be analysed using independent samples t-test and repeated measures analysis of variance (ANOVA). Nominal data will be analysed using chi-squared analysis.

Safety \& Tolerability Reports were reviewed with a Respiratory Consultant with specialist interest in Sleep Medicine on a regular basis and abnormal results were discussed in detail. If specific therapy is indicated on the basis of the research tests, the treating nephrologist will be informed and a management plan recommended.

02

Conditions studied

  • Renal Failure Chronic Requiring Hemodialysis
  • Sleep Disorders
03

In context

Sleep Wake Disorders

788 studies on the registry are indexed under Sleep Wake Disorders; 186 are open to participants now.

This study's planned enrollment of 60 is below the median of 114 across 215 observational studies indexed under Sleep Wake Disorders.

Browse Sleep Wake Disorders studies →

Lead sponsor

Beaumont Hospital is the lead sponsor of 19 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Sixty consecutive patients will be enrolled in the study over a period of 24 months. Patients were prioritized for recruitment if they were active on the transplant waitlist or a change in RRT modality was planned.

Inclusion criteria

  • >16 years old,
  • competent to independently undertake the informed consent process
  • currently on RRT or planned to start RRT in the next three months.

Exclusion criteria

Exclusion Criteria:

  • Patients consuming Benzodiazepine medication
  • Patients requiring nasal CPAP for sleep apnoea
  • Patients requiring supplemental oxygen
  • Patients with dementia, malignancy, or psychiatric disorder
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Interventions

  • DeviceVivia Home Hemodialysis System

    The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week

06

What researchers measure

Primary outcomes

  1. The prevalence of sleep disorders in a cohort of patients with advanced CKD/ESRD

    from the total sample population of 60

    Time frame: 18 months

Secondary outcomes

  1. Change in Subjective Sleep Quality following change of RRT modality

    Subjective sleep quality based on validated questionnaire

    Time frame: 6 months

  2. Change in objective sleep quality following change of RRT modality

    Objective sleep quality is measured by means of unattended home polysomnography for one night or wrist actigraphy for 3-5 consecutive nights

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Beaumont Hospital
    Dublin, 00, Ireland
    Recruiting
08

References and documents

Publications

  • Roumelioti ME, Brown LK, Unruh ML. The Relationship Between Volume Overload in End-Stage Renal Disease and Obstructive Sleep Apnea. Semin Dial. 2015 Sep-Oct;28(5):508-13. doi: 10.1111/sdi.12389. Epub 2015 May 5. PubMed 25940851 ↗
  • Loewen A, Siemens A, Hanly P. Sleep disruption in patients with sleep apnea and end-stage renal disease. J Clin Sleep Med. 2009 Aug 15;5(4):324-9. PubMed 19968009 ↗
  • Hanly P. Sleep disorders and home dialysis. Adv Chronic Kidney Dis. 2009 May;16(3):179-88. doi: 10.1053/j.ackd.2009.02.004. PubMed 19393968 ↗
  • Mallamaci F, Leonardis D, Tripepi R, Parlongo G, Catalano C, Tripepi G, Castronovo V, Ferini-Strambi L, Zoccali C. Sleep disordered breathing in renal transplant patients. Am J Transplant. 2009 Jun;9(6):1373-81. doi: 10.1111/j.1600-6143.2009.02653.x. Epub 2009 May 20. PubMed 19459802 ↗
  • Tang SC, Lam B, Lai AS, Pang CB, Tso WK, Khong PL, Ip MS, Lai KN. Improvement in sleep apnea during nocturnal peritoneal dialysis is associated with reduced airway congestion and better uremic clearance. Clin J Am Soc Nephrol. 2009 Feb;4(2):410-8. doi: 10.2215/CJN.03520708. Epub 2008 Dec 31. PubMed 19118118 ↗
  • Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med. 2001 Jan 11;344(2):102-7. doi: 10.1056/NEJM200101113440204. PubMed 11150360 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02583347
Lead sponsor
Beaumont Hospital
Collaborators
Baxter Healthcare Corporation
Responsible party
Claire Kennedy (Clinical Research Fellow, Beaumont Hospital) — Principal investigator
First posted
Oct 22, 2015
Start date
Dec 2015
Primary completion
Jul 2018 (estimated)
Completion
Jul 2018 (estimated)
Last update
Aug 28, 2017

Study contacts

Claire M Kennedy, MB, BMedSci
Contact
clairekennedy2@beaumont.ie
00353 1 8093000 ext. 739
Peter J Conlon, MB, MHS
Contact
PeterConlon@beaumont.ie
00353 1 8093000 ext. 2747
Peter J Conlon, MB, MHS
study director · Beaumont Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion